Lennox-Gastaut syndrome (LGS) is a severe epileptic encephalopathy with a prevalence of 1-2% of all patients with epilepsy. It is characterized by multiple pharmaco-resistant seizure types, including tonic, atypical absences and tonic or atonic drop attacks, and the presence of electroencephalographic abnormalities, such as slow-spike waves and paroxysmal fast rhythms. Intellectual disability, behavioural and psychiatric disorders are common comorbidities; these disturbances have a multi-factorial pathogenesis. The selection of the most appropriate drug must be tailored to each patient and guided by the prevalent seizure type. In this paper available pharmacological options are discussed and for each pharmacological agent, current evidence of efficacy and tolerability is provided. Valproic acid represents one of the first-line options in the treatment of LGS. Anyway, other antiepileptic drugs (AEDs) may be considered and added: lamotrigine, rufinamide, topiramate, clobazam can be efficacious. The use of felbamate must be carefully evaluated because of its adverse events. Perampanel, zonisamide, levetiracetam and fenfluramine have shown to be useful in the treatment of selected patients; nevertheless, the lack of RCTs does not allow to recommend their use in a systematic way. Recently, cannabidiol has provided high evidence of efficacy against LGS seizures; however, these data must be confirmed by long-term extensive studies and by trials comparing different AEDs, one to each other.
Definition, epidemiology and etiology
Lennox-Gastaut syndrome (LGS) is one of the most severe epileptic encephalopathies with childhood onset. It is characterized by the presence of (i) multiple, untreatable seizure types, including tonic seizures, atypical absences and tonic or atonic drop attacks, and (ii) electroencephalographic (EEG) abnormalities, consisting of interictal pattern of slow-spike waves (SSW) < 3 Hz, and paroxysmal fast rhythms (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) , mainly during non-REM sleep [1] . At the onset of the disorder, not all the different seizure types can be present [2] . In addition to the classic seizures core, patients with LGS can experience many other seizures, such as myoclonic, focal, and non-convulsive status epilepticus, especially in later stages of the disease. Although intellectual disability (ID) is seen in most patients, nevertheless it can also be absent; therefore, ID is not to be considered as a diagnostic criterion [3] .
LGS is a frequent epilepsy syndrome, accounting for 1-10% of all childhood epilepsies and for 0.6% of new-onset epilepsies [3] . Males are more prone to develop LGS than females with a M:F ratio of 1.3-1.6 [3] .
LGS is strictly connected to cognitive impairment; in fact, 7% of children with ID have LGS and 55% of patients diagnosed with LGS have a profound ID with an IQ < 20. LGS generally begins between the 2nd and the 8th year of life, with a peak of incidence between the 3rd and the 5th year of age [4] ; later onset is rare and often associated with specific conditions, such as Down syndrome [5] .
The etiology of LGS is heterogeneous; about two-thirds of cases are "symptomatic", while one third is defined as "cryptogenic", indicating that the cause has not yet been identified. Symptomatic cases may be due to brain injury (perinatal hypoxic-ischemic encephalopathy, cortical malformations, tuberous sclerosis complex, central nervous system (CNS) infections, and rarely, metabolic disorders) or to genetic etiology. To date, SCN1A, CHD2, FOXG1 and DNM1 mutations, in addition to rare copy number variants, have been reported to be implicated in the pathogenesis of LGS [3] . De novo mutations identified by exome sequencing in patients with LGS involved also GABRB3, ALG13, SCN2A, STXBP1 and CDKL5 genes [6] . The identification of the etiological cause depends strongly on the sophistication of the available tools. In this context, modern 3 T magnetic resonance (MR) scanners using specific sequences and new neurogenic investigations at disposition may have a key role in identifying the underlying etiology and reducing the portion of cryptogenic cases.
Epileptic and neurological symptoms

Patients with LGS experience several types of seizure
Tonic seizures are the prevalent type of seizures in LGS and the most typical one, so that it is considered as a fundamental requirement for the diagnosis. Tonic seizures can be not present at the onset of the disease and their prevalence varies widely. Tonic seizures can occur isolated or in series with increasing intensity; consciousness is frequently compromised. They can only affect the trunk, consisting of a flexion of the head and trunk, with apnea, opening of the mouth and revulsion of the eyeballs, occasionally preceded by crying, or can affect upper limbs with elevation, abduction, and flexion or shoulder elevation. If the patient is standing, tonic seizures can easily cause falls forward or backward.
Atypical absences are the second most common seizure type occurring in two thirds of patients with LGS. They start and end gradually and tend to last longer than typical absences. These may be accompanied by drooling, changes in postural tone, palpebral or perioral myoclonias and are generally not triggered by hyperventilation (HV) and by the intermittent photic stimulation (IPS) at EEG recording.
Drop attacks are found in more than half of the patients with LGS, although drop attacks are nearly impossible to count in wheel chaired patients. These seizures are of very short duration and involve a complete loss of consciousness. They can originate from atonic, tonic or, more rarely, myoclonic seizures [7] .
Other seizure types, including generalised tonic-clonic, generalised clonic, focal, reflex [[8] [5] ,] and non-epileptic psychogenic seizures [9] have been reported in patients with LGS.
Cognitive impairment and behavioural disturbances
Patients with LGS often have ID, behavioural and psychiatric disorders. ID is found in about half of patients at onset, usually associated with abnormalities at neuroimaging, and worsens over time, severely affecting more than two thirds of patients 5 years after diagnosis [[4] [10] ,]. The minority of patients with intellectual functioning at the lower limits of the normality show important difficulties in everyday life due to the slowing down of mental processes [2] . In cryptogenic cases, the psychomotor development of the child is generally normal before the onset of the disease and then deteriorates. However, the early onset, the presence of tonic seizures, certain EEG patterns and the overuse of antiepileptic drugs (AEDs) are risk factors for ID; on the contrary, the late onset, the presence of subclinical seizures without falls would have a positive role on cognitive functions [11] .
In addition to cognitive impairment, also behavioural disorders are often part of the clinical picture of patients making it even more difficult to manage affected children. Hyperactivity, insecurity, psychosis, aggression, hypokinesia, and autism spectrum disorders are present in about 50% of pati ents with LGS [[9] [12] ,]. These disturbances have a multi-factorial pathogenesis in which the epileptic activity, through the activation of specific abnormal networks, and the use of many comedications seems to play a key role [3] ; nocturnal seizures, by causing frequent sleep interruption, may deeply interfere with the memorylearning process, leading to cognitive and behavioural detrimental effects. In addition, some AEDs may also exacerbate comorbidities (ID, depression, mood alterations) either directly, or through a mechanism of drug interaction with other drugs, severely affecting the quality of life (QoL) of patients and their caregivers.
For all these reasons, co-morbidities in LGS patients should be managed carefully, through a multidisciplinary and individualized approach that would be able to meet the medical, physical, psychological and educational needs of each patient throughout the entire course of their life.
Ictal and interictal EEG abnormalities
EEG background activity is always abnormal in LGS patients; during wakefulness, disorganization and diffuse slowing with a poorly structured or absent posterior alpha dominant rhythm can be found; during sleep, EEG activity appears poorly structured, with variations of sleep architecture and a poor representation of physiological graphoelements.
Interictal EEG abnormalities
Interictal EEG can show focal (focal or multifocal spikes, spikewaves, polyspikes, slow waves and focal bursts of rapid rhythms) or generalized abnormalities. Focal alterations depend on the underlying pathology and are often related to a lesional origin of LGS, being not specific for this syndrome; these are usually observed during wakefulness and tend to become bisynchronous during sleep.
Main interictal EEG generalized abnormalities are typical SSW discharges at 1,5 -2.5 Hz during wakefulness and sleep which may not be present at the seizures onset [[ [2] ]]], [13] ]]] [14] ,], and synchronous diffuse or bilateral bursts of fast rhythms at 10-25 Hz, the so called "paroxysmal fast activity" (PFA), which is prevalent or exclusive of NREM sleep [[ [2] ]]], [15] ]]] [16] ,]. SSW discharges can last from a few seconds to a few minutes or have a sub-continuous course alternating with phases of EEG suppression. SSW complexes are generally followed by sinusoidal slow waves, while the bursts of fast rhythms may be irregular without a distinct onset and offset. SSW increase during the psycho-sensory relaxation, are little influenced by the HV and by the IPS, while they are inhibited or terminated by various stimuli (e.g. noise, eye opening and pain).
PFA generally lasts from 2 to many seconds and tend to be diffuse, synchronous and symmetric over both hemispheres, with a higher prevalence over fronto-central areas. When recorded during wakefulness this paroxysmal activity is correlated to tonic seizures. In one study [17] , the activation of a large part of cortex apparently sparing the primary cortices during PFA was described thanks to the use of functional magnetic resonance imaging (fMRI); moreover, PFA increased BOLD signal in some subcortical structures including the basal ganglia, thalamus, and brainstem [17] .
Ictal EEG abnormalities
Ictal EEG characteristics depend on the type of seizures
Tonic seizures: EEG correlates of tonic seizures consist of an overall desynchronization of EEG activity, with or without the presence of PFA. Four types of ictal patterns can be observed: desynchronization of the whole activity; PFA increasing progressively in amplitude; initial flattening followed by PFA; rhythmic discharge at 10-15 Hz, of high amplitude from the beginning. All these patterns can be preceded by a brief diffuse burst of SSW and usually followed by a brief period of diffuse slowed activity [15] .
Atypical Absences: EEG pattern is characterized by diffuse discharge of high amplitude SSW, at 1.5-2.5 Hz. The SSW are quite symmetric and predominant on the frontal regions. This pattern may be similar to the interictal one, except for greater amplitude and regularity [15] .
Drop Attacks: Atonic or myoclonic-atonic events are associated with diffuse polyspikes and wave complexes at EEG recording. Myoclonic drop attacks are accompanied by bursts of polyspikes or polyspikes and wave complexes. Brief tonic seizure may only produce a desynchronization of the EEG activity [15] .
Status Epilepticus (SE):
LGS patients can experience a convulsive SE or, more frequently, a NCSE. During SE the EEG pattern is similar to the interictal one. However, the diffuse SSW activity becomes more persistent and the EEG assumes the appearance of an atypical hypsarrhythmic pattern. This temporary worsening of the interictal EEG resumes its initial characteristics once the SE is finished [15] .
Differential diagnosis
A consistent overlap exists between LGS and other epileptic syndromes; therefore, the differential diagnosis may be particularly challenging. There is a high risk of underdiagnosis because some types of seizures may occur many months before the initial appearance of SSW at EEG recordings. Moreover, in the first five years of life, epileptic children can experience distinct types of seizures (febrile, clonic, myoclonic, atonic, myoclonic astatic, generalized tonic-clonic and absence seizures), which are common to various epileptic syndromes. Thus, without video-EEG monitoring during sleep, it would be very difficult to differentiate LGS from myoclonic astatic epilepsy (MAE, Doose syndrome), severe myoclonic epilepsy of infancy (SMEI, Dravet syndrome (DS)) and atypical benign partial epilepsy/pseudo-Lennox syndrome (ABPE/PLS) with continuous spike and waves during slow sleep (CSWS) [18] . The clinical course, age at onset and at remission of epileptic symptoms, seizures types at onset, further types of seizures that may occur later in life, EEG features, age at EEG normalization, and the hallmarks of each syndrome are reported in Table 1 . Patients with focal epilepsy showing clinical features typical of LGS, such as drop attacks and rapid EEG rhythms, have recently been described [19] . Anyway, these patients also showed distinctive traits, such as a later onset of epileptic symptoms, the ever-focal onset of seizures, including Table 1 The [17] [18] [19] [20] [21] [22] [23] [24] [25] drop attacks linked to focal asymmetrical tonic seizures, and a nonprogressive cognitive outcome. Therefore, repeated video-EEGs and polygraphic recordings during sleep and wakefulness, together with a correct interpretation of the data obtained and a careful medical history collection are essential for an early diagnosis, to minimize the risk for over-or underestimation of the LGS.
Therapeutic options: general principles of LGS treatment
LGS is a chronic and complex epileptic encephalopathy, associated with a high rate of drug resistance, despite the vast armamentarium of treatment options available today. Thus, the clinical management of the syndrome must take into account that seizure freedom is an unlikely goal and, therefore, the main objective should be to improve the patients' QoL, throughout a compromise between a complete seizures control and the prevention of adverse events (AEs) related to the administration of AEDs [1] . The pharmacological treatment should therefore be tailored to each patient, based on age, type of seizure and personal clinical history, reducing, where possible, the use of polytherapy [20] .
To date, there is little data available on the most appropriate antiepileptic therapy for patients with LGS. A recent 2013 Cochrane review comparing the efficacy of seven AEDs in the treatment of LGS, included eight studies and failed to assert the superiority of one drug on the others, or a high efficacy for any AED, as adjunctive therapy for LGS [21] . Thus, some old AEDs continue to be the mainstay of the treatment.
Herein, we present a critical review of literature, on the treatment of newly diagnosed "de novo" patients with LGS. Anyway, for the selection of the most appropriate AEDs or combination of drugs for a given patient with LGS, it is essential to consider mostly the prevalent type of seizures. The presence of comorbidities (behavioural and psychotic disturbances) and the risk of certain AEs associated to AEDs should also consistently influence therapeutic choices.
In conclusion, the long-term treatment goals must be defined taking into account the individual conditions.
Therapeutic options: the role of the old and new drugs
Valproic acid
Valproic acid (VPA) is first-generation AED with a complex and not fully elucidate mechanism of action. It is thought to potentiate GABA transmission by increasing GABA synthesis, reducing GABA turnover, and inhibiting GABA degradation and to reduce the release of the excitatory aminoacid β-hydroxybutyric acid; it also inhibits the N-metil-Daspartate (NMDA) receptor-mediated excitatory transmission, blockades voltage-gated sodium channels (VGSCs) and calcium channels, potentiates calcium-activated potassium currents and modulates serotonergic and dopaminergic neurotransmission [22] .
First approved as anticonvulsant drug by European Medicines Agency (EMA) in 1967 and by Food and Drug Administration (FDA) in 1978, VPA has never been licensed for LGS; anyway, many experts agree that this broad-spectrum AED should be the first line therapeutic option for children with emerging LGS [[1] [20] ,]. In fact, most patients with epilepsy featuring generalized or multiple seizure types are initially prescribed VPA, due to the wide efficacy of this AED against several types of seizures and the extremely low probability of determining a seizures worsening [1] . In patients with LGS, VPA has shown to be useful in reducing myoclonic, atypical absence, and atonic seizures [23] .
In an uncontrolled, observational study [24] involving 336 epileptic patients, 38 of whom with LGS, VPA therapy (as monotherapy or in combination with at least one AED among primidone, phenytoin, ethosuximide, acetazolamide, or benzodiazepines) was responsible for a complete seizure control in 8 (21%), and ≥50% seizure improvement in 21 individuals (55%) [24] . Better seizure outcomes were obtained in patients with drop attacks, followed by atypical absences and myoclonic seizures, while lower responder rates were reported for tonic and tonic-clonic seizures [24] .
In pediatric population, VPA therapy has been associated with different AEs: somnolence, weight gain, hair loss, dizziness, hyperammonaemia, and hypocarnitinaemia [25] . Thrombocytopenia and coagulopathies can also occur in 5-40% and in 4% of children receiving VPA, respectively, and seem to be concentration-dependent [26] . Most serious ADRs include hepatotoxicity and pancreatitis, potentially leading to fatalities, especially in children taking polytherapy and of early age [27] .
Lamotrigine
Lamotrigine (LTG) is a second-generation AED which acts by stabilizing the presynaptic membrane through the blockade of VGSCs and by preventing the release of excitatory neurotransmitters, primarily glutamate. First marketed in the UK in 1991 and approved for antiepileptic use in the US in 1994, LTG was approved by FDA as adjunctive treatment for LGS patients ≥ 2 years old in 1998 [28] .
Indeed, LTG was effective and well tolerated as add-on therapy in a multicenter Phase III placebo-controlled randomized controlled trial (RCT) [29] conducted in 169 LGS individuals, aged 3-25 years, who showed overall reduction (≥50% frequency per week) in absence seizures, drop attacks, tonic-clonic seizures and all seizure types after 16 weeks of treatment with LTG, when compared with placebo. LTG was well tolerated and improved seizure frequency in a double-blind, placebo-controlled, crossover study [30] involving 30 children and adolescents with drug-resistant generalized epilepsy, 20 of whom had LGS. These data were also confirmed in a Cochrane review of RCTs [21] analysing efficacy of LTG, topiramate (TPM), rufinamide (RUF), an analogue of thyrotropin releasing hormone, and cinromide therapies in patients with LGS; LTG was found to reduce the frequency of all seizure types compared with placebo (-32% vs -9%; p = 0·02), showing the highest efficacy against drop attacks [29] . Conversely, LTG should not be used in myoclonic seizures, since it can have a worsening effect [31] . Although being overall less effective than TPM in controlling seizures, as assessed in one RCT [32] involving a large cohort of 716 patients with generalised and unclassifiable epilepsy who were randomly assigned to receive VPA, LTG or TPM, LTG is considered by many experts the best choice as second AED in LGS in case of failure of VPA. Common AEs include rash, drowsiness, anorexia, headache, and ataxia [20] , but LTG can also lead to behavioural manifestations, such as aggression, irritability and agitation [1] . Skin reaction is the most frequently reported AE in children, occurring in 7.3% of patients, and represents the first cause of drug discontinuation; fortunately, serious skin reactions are rare, with a risk of 0.09% for Stevens-Johnson syndrome [33] ; higher likelihood to occur when LTG is given in combination with VPA [34] . LTG has few, but clinically relevant drug interactions. A synergistic pharmacodynamic interaction is seen with VPA; moreover, comedication with VPA can cause a 50% reduction of LTG clearance with a higher risk of AEs; on the contrary, the concomitant administration of enzyme-inducing AEDs such as carbamazepine, oxcarbazepine, phenytoin, and phenobarbital augments LTG clearance, lowering drug serum levels. Consequently, lower dosage is required when LTG is used as adjunctive therapy to VPA; conversely, VPA discontinuation requires an augment of LTG dose [35] . Thus, when these two AEDs are administered concomitantly, drug serum levels and clinical monitoring are recommended [36] .
Rufinamide
RUF is a third generation-AED which acts by suppressing neuronal excitability throughout prolongation of voltage gated sodium channels inactivation, leading to a decreased frequency of sustained repetitive firing [37] . RUF was approved in 2007 by EMA and in 2008 by FDA as adjunctive therapy for seizures associated with LGS in patients ≥ 4 years old [38] . Effectiveness and safety of RUF in the treatment of LGS [17] [18] [19] [20] [21] [22] [23] [24] [25] were assessed in two RCTs [39] [40] [41] and in their long-term open label extension studies [42] . In a phase III placebo-controlled RCT [41] involving 138 LGS patients, RUF was able to significantly reduce the total seizure frequency, mostly of drop attacks.
In the subsequent open-label extension study [42] , RUF demonstrated to maintain long-term efficacy and tolerability, determining a ≥ 50% reduction in the frequency of total seizure in 41% and of drop attacks in 47.9% of LGS patients. More recently, efficacy and safety of RUF as adjunctive therapy for LGS were also evaluated in one RCT [39] involving 58 Japanese patients, who received RUF as adjunctive therapy or placebo, and in its long-term follow up study [40] . Patients taking RUF maintained a reduction of total seizure frequency (47.4%) and of tonic-atonic seizures (36.1%) until 52 weeks from baseline. All AEs were mild or moderate, except for transient seizure aggravation; while decreased appetite, drug eruption, and worsening of underlying autism resulted in drug discontinuation in 3.7%, 1.9%, and 1.9% of patients, respectively [40] . A recent Cochrane review [43] evaluating the efficacy and tolerability of RUF as adjunctive treatment in patients with focal refractory epilepsy and LGS from randomised, double-blind, placebo-controlled trials, confirmed an overall effectiveness of RUF in reducing seizure frequency of at least 50%, compared with placebo. Data coming from prospective open-label and retrospective studies [44] [45] [46] [47] support the consistent efficacy and generally favourable safety/tolerability profile of RUF when used as add-on treatment in LGS patients, also in infants and children aged less than 4 years [48] . Thus, RUF would be a suitable AED as second adjunctive therapy, once VPA and LTG have failed [1] . In some cases, due to its efficacy against drop attacks, RUF could be preferred to other AEDs. To date the use of RUF has been approved only for children of at least 4 years, but a recent open label study [49] analysing RUF safety and tolerability during 6 month-period in a sample of 37 LGS children aged between 1 and 4 years, found comparable safety and pharmacokinetic profiles between the two age-groups.
Topiramate
TPM is a second-generation AED with several mechanisms of action; its antiepileptic properties depend on enhancement of (GABA)ergic inhibition on postsynaptic GABA-A receptors, blockage of VGSCs, and suppression of the AMPA/kainite receptors. TPM was approved in 2001 by the FDA as adjunctive therapy for the treatment of seizures associated with LGS in patients of 2 years of age and older [50] .
TPM efficacy and tolerability in LGS patients were assessed in one placebo-controlled RCT and in its long-term extensive study [51] . The double-blind RCT included 98 LGS patients who were randomly assigned to receive TPM or placebo for 11-week period. A relevant reduction in the frequency of drop attacks and of major seizures was reported in TPM group, compared with placebo (−14.8 vs. + 5.1%; p = 0.041) and (−25.8 vs. + 5.2%; p = 0.015), respectively [51] . Moreover, significantly greater ≥50% seizure frequency reduction from baseline was found for patients taking TPM, compared with placebo (33 vs. 8%; p = 0.002). During maintenance period, freedom from drop attacks was achieved by 10.9% of TPM group vs. 0% placebo group. Patients completing the RCT (96), were recruited into an openlabel extension study with flexible TPM dosage [52] . After 6 months of treatment, 55% of patients taking TPM showed a ≥50% reduction in the frequency of drop attacks with respect to baseline, and 15% remained drop attacks free for at least 6 months.
Effectiveness of TPM and LTG in reducing tonic/atonic seizures in LGS patients was also supported by the American Academy of Neurology and the American Epilepsy Society [53] .
After the failure of VPA as monotherapy, combination of two AEDs was the most prescribed second-line treatment in LGS (57%), followed by a different monotherapy with TPM or LTG (38%), as emerged by a study analysing therapeutic strategies in the management of LGS [54, 55] .
In children, TPM shows an overall safety profile: most common AEs tend to occur early in the treatment and are CNS-related (somnolence, psychomotor slowing, in addition to cognitive and behavioural disorders). Anorexia and weight loss are also reported, without a longterm impact on growth [56] .
Felbamate
This second-generation AED has multiple mechanisms of action, including modulation of VGSCs, inhibition of voltage-activated calcium channels, modulation of GABA-A receptors, and inhibition of NMDA receptor currents [57] .
Due to the elevated risk of aplastic anaemia and acute liver failure, FBM has never been approved by EMA; anyway, in some European countries, it was licenced as adjunctive therapy in children, adolescents, and adults with LGS in whom previous AEDs failed to achieve seizure control [58] . In US, FBM therapy for LGS was approved also as monotherapy for patients with severe refractory epilepsy for whom treatment-related benefit in terms of seizure control are evident. FBM efficacy as adjunctive treatment in LGS was assessed in a placebocontrolled RCT [59] and in its open label-extensive study [60] . The RCT [59] included 73 LGS patients aged 4-36 years who were randomly assigned to receive FBM or placebo during 70-day treatment period and 56-day maintenance period. During treatment period, significantly higher reduction in all seizure types was reported for FLB, compared with placebo group (−19 vs. + 4%; p = 0.002); atonic seizures were considerably reduced in patients taking FLB vs. placebo (−34 vs. − 9%; p = 0.01) with atonic seizure freedom being achieved in 10.7% of FBM group individuals. During maintenance period, significantly greater reduction in all seizure types, in atonic, and in generalized tonic-clonic seizures was described for FLB compared with placebo group (−26 vs. + 5%; p < 0.001, −44 vs. − 7%; p = 0.002, and −40 vs. + 12%; p = 0.017, respectively). Eighteen percent of individuals on FBM treatment had no drop attacks. Patients completing the RCT entered into a 12-month open-label follow up study [60] which confirmed the long-term efficacy of FBM in LGS, with > 50% frequency reduction from baseline reported to be of 50% for total seizures and of 67% for drop attacks.
Clobazam
Clobazam (CLB) is a 1,5-benzodiazepine with antiepileptic properties. It binds to postsynaptic GABAA receptors, causing hyperpolarization of the neuron and, consequently, an increase of the action potential threshold which will reduce the frequency of action potentials and, therefore, the likelihood of seizures [61] . CLB was approved in 2011 by FDA as adjunctive treatment for LGS patients two years and older. In Europe it is licensed as add-on therapy for refractory epilepsy and epileptic syndromes [62] . Effectiveness and safety of CLB in LGS were evaluated in a phase II study [63] , a phase III placebo-controlled RCT [64] and in their open-label follow up study [65] . Sixty-eight LGS patients with drop attacks aged 2-26 years were recruited in a phase II study [63] to receive low-or high-dose CLB; CLB at higher dosage was more effective than CLB at lower dosage in reducing the frequency of drop attacks and all seizure types. Patients completing the trial entered a phase III placebo-controlled RCT [64] , which included 238 LGS patients aged 2-60 years, who were randomly assigned to receive CLB at different dosages or placebo as adjunctive treatment during a period of 12 weeks. CLB was effective with a great reduction in drop attacks and in all seizure types at any dose. Freedom from drop attacks was achieved by 3.5% of placebo group compared with 7.5, 12.1, and 24.5% of CLB 0.25, 0.5, and 1 mg/kg/day group, respectively. Patients completing the two trials were enrolled in a long-term, follow up study [65] . (n = 267) which demonstrated the long-term efficacy of add-on CLB in the treatment of seizures associated with LGS [65] . Recent post hoc analysis [66] conducted on 200 LGS patients on adjunctive CLB over a 2 year-period, found that tolerance to the anticonvulsant action of the drug (defined as a dosage increase > 40% associated with an increase in seizure frequency) occurred in a minority of patients, probably being overestimated. A further post hoc analysis [67] found that ≥20% increases in CLB dosage during long-term treatment improved seizure control in more than 80% of LGS patients who had previously responded to the drug during lead-in treatment, suggesting that individuals showing seizure improvement at low starting CLB dosages may further benefit from additional increments of the dose, with a low likelihood of developing tolerance. CLB is associated with relevant effects on cognition and behaviour, in addition to respiratory tract infections [62] . In conclusion, CLB is recommended for an initial intermittent use, in case of cluster seizures, prolonged absences or NCSE, and for a regular use in patients featuring particularly drug-resistant drop-attacks [1].
Other AEDs
Data coming from prospective and observational studies [68-71] support the potential efficacy of other broad-spectrum AEDs, such as Zonisamide (ZNS), Levetiracetam (LEV), Perampanel (PER) and Fenfluramine (FFA) in the treatment of LGS.
ZNS is a second-generation AED which acts by inhibiting neuronal VGSCs and low-voltage-activated calcium channels, in addition to having GABAergic properties [72] . It was approved by FDA as adjunctive treatment in the management of refractory partial onset seizures, in adults and children aged six years and above. ZNS effectiveness and tolerability were evaluated in a prospective, multicentre, open-label study [69] , including 62 LGS patients aged between 6 months and 18 years, who received ZNS ad add-on therapy for at least 12 months. ZNS was found to be effective and well tolerated with complete seizure control achieved by 4.8% and ≥50% seizure reduction by 46.8%, while 9.7% and 38.7% of patients had < 50% seizure reduction and no reduction, respectively [69] . Common AEs (somnolence and anorexia) were transient and of mild severity, not requiring discontinuation of the drug [69] .
LEV is a second-generation AED with a mechanism of action partially unknown: it binds to Synaptic Vesicle protein 2 (SV2) in the presynaptic terminal and is implicated in Ca 2+ homeostasis [73] . The use of LEV as adjunctive treatment was assessed in an open-label, multicentre, observational study [68] involving 55 LGS patients during an 8week maintenance period. Seizure freedom was reported by 27.3%, > 50% seizure reduction by 58.2%, with a relevant efficacy against drop attacks [68] . The most frequent AE was hyperactivity [68] . Combination of VPA, CLB, and LEV was found to be an appropriate treatment for LGS patients, in a prospective follow up study including 43 individuals [74] .
PER is a selective non-competitive antagonist of AMPA receptors [75] , It was administrated as add-on therapy to 58 children and adolescents with refractory epilepsies, including five with LGS, showing ≥50% seizure frequency reduction in 31% and seizure freedom in 9.1% [70] . PER as adjunctive treatment was also assessed in a prospective study, involving a small sample-13 LGS patients-who received PER for a mean period of 10.8 months [71] . A ≥ 50% reduction in total seizure frequency was reported for 9 patients (69.2%), while 4 had nor improvement, neither seizure worsening, indicating a potential utility of PER in LGS. Common AEs were reduced vigilance, fatigue, and behavioural alterations [70] .
FFA is a derivative of amphetamine which had been widely used in Europe since 1963 to treat obesity. This compound enhances serotoninergic transmission by promoting serotonin release, and by inhibiting serotonin reuptake into brain synapses; it also contrasts dopaminergic transmission and has effect on the sigma 1 receptors [76] . Its antiepileptic properties were discovered at the beginning of 1980s, when FFA was successfully used in the treatment of some epileptic encephalopathies, as reported in small case series [77] [78] [79] . In the last few years, it has been considered as adjunctive treatment for LGS and DS, showing great efficacy in DS patients [80] [81] [82] , as confirmed by preliminary data from a phase III RCT [83] . Its potential efficacy against seizures associated with LGS has been recently assessed in a phase II open-label dose finding study, including 13 patients aged 3-18 years who were administered add-on FFA for a period of 20 weeks; afterwards, responders were offered to enter a long-term extension trial. FFA was effective, causing a ≥50% and ≥75% seizure reduction in 62% and 23% of patients, respectively, after 20 weeks, and in 67% and 33% of patients, respectively, after 15 months of treatment. FFA therapy was substantially well tolerated in this small sample of LGS individuals [84] . A phase III RCT of add-on FFA in the treatment of LGS is still ongoing.
Cannabidiol
Cannabidiol (CBD) is an unconventional compound which exerts antiepileptic properties through a novel multiple mechanism of action. In recent years, CBD has been used, in experimental way and at different dosages in children and adults, to treat several drug-resistant epilepsies, including LGS, with promising results in terms of long-term seizure frequency reduction and safety [85] . The efficacy and safety of CBD as add-on anticonvulsant therapy for patients with LGS has been assessed in two phase III placebo-controlled RCTs [86, 87] ; the former [86] involved 171 individuals with refractory seizures from 24 different clinical sites, who were randomly assigned to receive 20 mg/kg oral CBD daily or placebo during a 14-week treatment period. Add-on CBD was overall effective and generally well tolerated, showing a median percentage reduction in monthly drop seizure frequency from baseline of 43.9% in the CBD group, compared with 21.8% in the placebo group. Main AEs reported were mild or moderate (diarrhoea, somnolence, pyrexia, decreased appetite, and vomiting); a transient elevation in transaminase levels was also reported, especially in patients taking concomitant VPA. The second placebo-controlled multicentre RCT [87] involved 225 patients with LGS who were randomized to receive 20 mg/kg, 10 mg/kg oral cannabidiol daily or placebo for 14 weeks. Results confirmed the efficacy of the addition of CBD at both dosages of 10 and 20 mg/kg/day to a conventional anticonvulsant therapy in significantly reducing drop seizures frequency. In conclusion, these two RCTs provided class 1 evidence about the efficacy of CBD as antiepileptic agent in specific epileptic syndromes; however, it is not yet clear how much is due to the direct effect of the CBD itself and how much instead to its interaction with the metabolism of concomitant drugs (e.g. CLB). Further investigations will define the exact role of this new promising anticonvulsant agent [88] .
Conclusion
LGS is a 'broad' electroclinical syndrome characterized by heterogeneous aetiology, variable comorbidities, including different degrees of intellectual disability; thus, a revision of the old terminology would be appropriate. Nevertheless, the main features of the syndrome (i.e. distinctive seizure types and EEG findings) are very helpful to collect patients with a homogeneous core phenotype to address genetic studies or to evaluate the effect of specific treatments.
Seizures in LGS are difficult to treat, and seizures freedom often remains a utopia; therefore, physicians' main objective must be to reduce the frequency and severity of seizures by using as few antiepileptic drugs as possible, in order to improve the patient's QoL. In this regard, antiepileptic therapy should be as tailored as possible to each patient, taking into account his clinical history, comorbidities and, above all, the type of seizure. Despite the wide availability of new antiepileptic drugs, VPA is still considered as one of the first line options by many physicians for the treatment of "de novo" LGS. The use of LTG, RUF, TPM, or CLB has been shown to be effective in reducing the frequency of seizures; other possible effective AEDs, for which the level of evidence is not yet consistent, are ZNS, LEV, PER and FFA. (In Table 2 , the main data of efficacy from RCTs in LGS and DS are reported). Cannabiodiol has now reached class I evidence of efficacy as anticonvulsant agent in certain epileptic syndromes, including LGS (above all against drop attacks) and DS, so its use should be recommended in these [17] [18] [19] [20] [21] [22] [23] [24] [25] patients, once other treatments have failed. However, there are currently no approved guidelines on the most appropriate antiepileptic drug therapy for patients with LGS; therefore, further well-designed, long-term RCTs including large populations' samples, are required. In particular, 'days with and without seizures (drop) clusters' rather than the raw seizure frequency, should be indicated as primary endpoints of efficacy, since drop attacks still represent the major concern in these patients. The control of tonic/atonic attacks is in fact the most difficult challenge to deal with and the reason why there are so many drugs on the market introduced as "orphan drugs for LGS". Currently the AEDs available for LGS are symptomatic drugs, used to treat the symptom "epilepsy" itself, but not to modify the natural history of the disease that so severely affects the patients' QoL. The challenge for the near future will be to guide therapeutic choices based on etiology. Thus, next to the pharmacological approach, great emphasis will be given to a selective, surgical approach, that would allow a more precocious control of epileptogenesis. Indeed, an early seizures control has been associated with better neurocognitive endpoint. Other potential fields of future research will include other non-AED treatments and their potentiality to protect against cognitive impairment and even improve intellectual functions; in this regard the therapy with steroids, CBD and FFA will be carefully assessed in RCTs, in order to confirm their efficacy and, above all, to test their safety and tolerability in LGS patients.
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